Aquinox Pharmaceuticals commences phase II clinical trial of AQX-1125 in bladder pain syndrome / interstitial cystitis

Aquinox Pharmaceuticals Inc., a private, venture-backed, pharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory disease, have announced that it has begun dosing patients in a Phase II clinical trial of its lead clinical candidate, AQX-1125, a potent SHIP1 activator, for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC). The trial, known as the LEADERSHIP study, is being conducted at community and academic sites across Canada evaluating the safety and efficacy of AQX-1125 in approximately 70 BPS/IC patients...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Urology / Nephrology Source Type: news